ArticlePloS one2020
Immune modulatory effect of a novel 4,5-dihydroxy-3,3´,4´-trimethoxybibenzyl from Dendrobium lindleyi.
Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 29 citations in OpenAlex.
- Immunomodulatory Potential of a Bibenzyl-dihydrophenanthrene Derivative Isolated fromJournal of natural products · 2025Article
- Biological Characteristics of a Novel Bibenzyl Synthase (Molecules (Basel, Switzerland) · 2024Article
- Biological Potential of Bioactive Bibenzyl Compound Chrysotoxine from the Genus Dendrobium in Medicine.Current drug research reviews · 2024Article
- Diverse modulatory effects of bibenzyls from Dendrobium species on human immune cell responses under inflammatory conditions.PloS one · 2024Article
- Structural diversification of bioactive bibenzyls through modular co-culture leading to the discovery of a novel neuroprotective agent.Acta pharmaceutica Sinica. B · 2023Article
- Differential compartmentalization of myeloid cell phenotypes and responses towards the CNS in Alzheimer's disease.Nature communications · 2022Article
- Recent Research Progress on Natural Stilbenes inMolecules (Basel, Switzerland) · 2022Review
- Characterization of the Key Bibenzyl Synthase inInternational journal of molecular sciences · 2022Article
- Moscatilin suppresses the inflammation from macrophages and T cells.Open medicine (Warsaw, Poland) · 2022Article
- Four Novel Phenanthrene Derivatives withMolecules (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dendrobium bibenzyls and phenanthrenes such as chrysotoxine, cypripedin, gigantol and moscatilin have been reported to show promising inhibitory effects on lung cancer growth and metastasis in ex vivo human cell line models, suggesting their potential for clinical application in patients with lung cancer. However, it remains to be determined whether these therapeutic effects can be also seen in primary human cells and/or in vivo. In this study, we comparatively investigated the immune modulatory effects of bibenzyls and phenanthrenes, including a novel Dendrobium bibenzyl derivative, in primary human monocytes. All compounds were isolated and purified from a Thai orchid Dendrobium lindleyi Steud, a new source of therapeutic compounds with promising potential of tissue culture production. We detected increased frequencies of TNF- and IL-6-expressing monocytes after treatment with gigantol and cypripedin, whereas chrysotoxine and moscatilin did not alter the expression of these cytokines in monocytes. Interestingly, the new 4,5-dihydroxy-3,3',4'-trimethoxybibenzyl derivative showed dose-dependent immune modulatory effects in lipopolysaccharide (LPS)-treated CD14lo and CD14hi monocytes. Together, our findings show immune modulatory effects of the new bibenzyl derivative from Dendrobium lindleyi on different monocyte sub-populations. However, therapeutic consequences of these different monocyte populations on human diseases including cancer remain to be investigated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.